{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T14:51:53Z","timestamp":1783003913339,"version":"3.54.5"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,12,19]],"date-time":"2022-12-19T00:00:00Z","timestamp":1671408000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,12,19]],"date-time":"2022-12-19T00:00:00Z","timestamp":1671408000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001711","name":"Schweizerischer Nationalfonds zur F\u00f6rderung der Wissenschaftlichen Forschung","doi-asserted-by":"publisher","award":["320030_141179"],"award-info":[{"award-number":["320030_141179"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008947","name":"Stiftung Synapsis - Alzheimer Forschung Schweiz AFS","doi-asserted-by":"publisher","award":["2017-PI01"],"award-info":[{"award-number":["2017-PI01"]}],"id":[{"id":"10.13039\/501100008947","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Alz Res Therapy"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Introduction<\/jats:title>\n                <jats:p>Neuropsychiatric symptoms are important treatment targets in the management of dementia and can be present at very early clinical stages of neurodegenerative diseases. Increased cortisol has been reported in Alzheimer\u2019s disease (AD) and has been associated with faster cognitive decline. Elevated cortisol output has been observed in relation to perceived stress, depression, and anxiety. Dehydroepiandrosterone sulfate (DHEAS) has known anti-glucocorticoid effects and may counter the effects of cortisol.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Objectives<\/jats:title>\n                <jats:p>We aimed to examine whether CSF cortisol and DHEAS levels were associated with (1) neuropsychiatric symptoms at baseline, (2) changes in neuropsychiatric symptoms over 3 years, and (3) whether these associations were related to or independent of AD pathology.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>One hundred and eighteen participants on a prospective study in a memory clinic setting, including patients with cognitive impairment (<jats:italic>n<\/jats:italic> = 78), i.e., mild cognitive impairment or mild dementia, and volunteers with normal cognition (<jats:italic>n<\/jats:italic> = 40), were included. Neuropsychiatric symptoms were assessed using the Neuropsychiatric Inventory Questionnaire (NPI-Q). CSF cortisol and DHEAS, as well as CSF AD biomarkers, were obtained at baseline. Neuropsychiatric symptoms were re-assessed at follow-up visits 18 and 36 months from baseline. We constructed linear regression models to examine the links between baseline neuropsychiatric symptoms, the presence of AD pathology as indicated by CSF biomarkers, and CSF cortisol and DHEAS. We used repeated-measures mixed ANCOVA models to examine the associations between the neuropsychiatric symptoms\u2019 changes over time, baseline CSF cortisol and DHEAS, and AD pathology.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Higher CSF cortisol was associated with higher NPI-Q severity scores at baseline after controlling for covariates including AD pathology status (<jats:italic>B<\/jats:italic> = 0.085 [0.027; 0.144], <jats:italic>p<\/jats:italic> = 0.027; <jats:italic>r<\/jats:italic> = 0.277). In particular, higher CSF cortisol was associated with higher baseline scores of depression\/dysphoria, anxiety, and apathy\/indifference. Elevated CSF cortisol was also associated with more marked increase in NPI-Q scores over time regardless of AD status (<jats:italic>p<\/jats:italic> = 0.036, <jats:italic>\u03b7<\/jats:italic><jats:sup>2<\/jats:sup> = 0.207), but this association was no longer significant after controlling for BMI and the use of psychotropic medications. CSF DHEAS was associated neither with NPI-Q scores at baseline nor with their change over time. Cortisol did not mediate the association between baseline NPI-Q and changes in clinical dementia rating sum of boxes over 36 months.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Higher CSF cortisol may reflect or contribute to more severe neuropsychiatric symptoms at baseline, as well as more pronounced worsening over 3 years, independently of the presence of AD pathology. Our findings also suggest that interventions targeting the HPA axis may be helpful to treat neuropsychiatric symptoms in patients with dementia.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13195-022-01139-9","type":"journal-article","created":{"date-parts":[[2022,12,19]],"date-time":"2022-12-19T04:10:59Z","timestamp":1671423059000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Persisting neuropsychiatric symptoms, Alzheimer\u2019s disease, and cerebrospinal fluid cortisol and dehydroepiandrosterone sulfate"],"prefix":"10.1186","volume":"14","author":[{"given":"Sami","family":"Ouanes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Rabl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Clark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clemens","family":"Kirschbaum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julius","family":"Popp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,12,19]]},"reference":[{"issue":"6","key":"1139_CR1","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1002\/gps.5500","volume":"36","author":"TH Edwin","year":"2021","unstructured":"Edwin TH, Strand BH, Persson K, Engedal K, Selbaek G, Knapskog AB. Neuropsychiatric symptoms and comorbidity: associations with dementia progression rate in a memory clinic cohort. International journal of geriatric psychiatry. 2021;36(6):960\u20139.","journal-title":"International journal of geriatric psychiatry"},{"key":"1139_CR2","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.jad.2015.09.069","volume":"190","author":"QF Zhao","year":"2016","unstructured":"Zhao QF, Tan L, Wang HF, Jiang T, Tan MS, Tan L, et al. The prevalence of neuropsychiatric symptoms in Alzheimer\u2019s disease: systematic review and meta-analysis. Journal of affective disorders. 2016;190:264\u201371.","journal-title":"Journal of affective disorders"},{"issue":"8","key":"1139_CR3","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0161092","volume":"11","author":"H Kazui","year":"2016","unstructured":"Kazui H, Yoshiyama K, Kanemoto H, Suzuki Y, Sato S, Hashimoto M, et al. Differences of behavioral and psychological symptoms of dementia in disease severity in four major dementias. PloS one. 2016;11(8):e0161092.","journal-title":"PloS one"},{"issue":"2","key":"1139_CR4","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1017\/S104161021700151X","volume":"30","author":"F Sheikh","year":"2018","unstructured":"Sheikh F, Ismail Z, Mortby ME, Barber P, Cieslak A, Fischer K, et al. Prevalence of mild behavioral impairment in mild cognitive impairment and subjective cognitive decline, and its association with caregiver burden. International psychogeriatrics \/ IPA. 2018;30(2):233\u201344.","journal-title":"International psychogeriatrics \/ IPA"},{"key":"1139_CR5","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2022.892754","volume":"14","author":"S Ouanes","year":"2022","unstructured":"Ouanes S, Clark C, Richiardi J, Marechal B, Lewczuk P, Kornhuber J, et al. Cerebrospinal fluid cortisol and dehydroepiandrosterone sulfate, Alzheimer\u2019s disease pathology, and cognitive decline. Front Aging Neurosci. 2022;14:892754.","journal-title":"Front Aging Neurosci"},{"issue":"7","key":"1139_CR6","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1002\/gps.4704","volume":"32","author":"TM Terum","year":"2017","unstructured":"Terum TM, Andersen JR, Rongve A, Aarsland D, Svendsboe EJ, Testad I. The relationship of specific items on the Neuropsychiatric Inventory to caregiver burden in dementia: a systematic review. International journal of geriatric psychiatry. 2017;32(7):703\u201317.","journal-title":"International journal of geriatric psychiatry"},{"issue":"1","key":"1139_CR7","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1136\/jnnp-2014-308112","volume":"86","author":"J Wang","year":"2015","unstructured":"Wang J, Yu JT, Wang HF, Meng XF, Wang C, Tan CC, et al. Pharmacological treatment of neuropsychiatric symptoms in Alzheimer\u2019s disease: a systematic review and meta-analysis. Journal of neurology, neurosurgery, and psychiatry. 2015;86(1):101\u20139.","journal-title":"Journal of neurology, neurosurgery, and psychiatry"},{"issue":"1","key":"1139_CR8","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s40035-021-00236-3","volume":"10","author":"KP Ng","year":"2021","unstructured":"Ng KP, Chiew H, Rosa-Neto P, Kandiah N, Ismail Z, Gauthier S. Associations of AT(N) biomarkers with neuropsychiatric symptoms in preclinical Alzheimer\u2019s disease and cognitively unimpaired individuals. Transl Neurodegener. 2021;10(1):11.","journal-title":"Transl Neurodegener"},{"issue":"1","key":"1139_CR9","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s13195-021-00949-7","volume":"14","author":"B Creese","year":"2022","unstructured":"Creese B, Ismail Z. Mild behavioral impairment: measurement and clinical correlates of a novel marker of preclinical Alzheimer\u2019s disease. Alzheimers Res Ther. 2022;14(1):2.","journal-title":"Alzheimers Res Ther"},{"key":"1139_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2020.101171","volume":"64","author":"B Zheng","year":"2020","unstructured":"Zheng B, Tal R, Yang Z, Middleton L, Udeh-Momoh C. Cortisol hypersecretion and the risk of Alzheimer\u2019s disease: a systematic review and meta-analysis. Ageing Res Rev. 2020;64:101171.","journal-title":"Ageing Res Rev"},{"key":"1139_CR11","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.neurobiolaging.2020.05.006","volume":"94","author":"S Ouanes","year":"2020","unstructured":"Ouanes S, Castelao E, von Gunten A, Kuehner C, Preisig M, Popp J. Salivary cortisol and five-year change in cognitive performance in non-demented elderly subjects: a population-based study. Neurobiol Aging. 2020;94:34\u20137.","journal-title":"Neurobiol Aging"},{"key":"1139_CR12","doi-asserted-by":"publisher","first-page":"43","DOI":"10.3389\/fnagi.2019.00043","volume":"11","author":"S Ouanes","year":"2019","unstructured":"Ouanes S, Popp J. High cortisol and the risk of dementia and Alzheimer\u2019s disease: a review of the literature. Front Aging Neurosci. 2019;11:43.","journal-title":"Front Aging Neurosci"},{"issue":"4","key":"1139_CR13","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1177\/070674379704200409","volume":"42","author":"SJ Kiraly","year":"1997","unstructured":"Kiraly SJ, Ancill RJ, Dimitrova G. The relationship of endogenous cortisol to psychiatric disorder: a review. Canadian journal of psychiatry Revue canadienne de psychiatrie. 1997;42(4):415\u201320.","journal-title":"Canadian journal of psychiatry Revue canadienne de psychiatrie"},{"key":"1139_CR14","doi-asserted-by":"crossref","unstructured":"Dziurkowska E, Wesolowski M. Cortisol as a biomarker of mental disorder severity. J Clin Med. 2021;10(21):5204.","DOI":"10.3390\/jcm10215204"},{"issue":"2","key":"1139_CR15","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/S0278-2626(02)00519-5","volume":"50","author":"VM de Bruin","year":"2002","unstructured":"de Bruin VM, Vieira MC, Rocha MN, Viana GS. Cortisol and dehydroepiandosterone sulfate plasma levels and their relationship to aging, cognitive function, and dementia. Brain and cognition. 2002;50(2):316\u201323.","journal-title":"Brain and cognition"},{"issue":"2","key":"1139_CR16","doi-asserted-by":"publisher","first-page":"141","DOI":"10.2174\/1567205017666200317092310","volume":"17","author":"DS Strac","year":"2020","unstructured":"Strac DS, Konjevod M, Perkovic MN, Tudor L, Erjavec GN, Pivac N. Dehydroepiandrosterone (DHEA) and its sulphate (DHEAS) in Alzheimer\u2019s disease. Curr Alzheimer Res. 2020;17(2):141\u201357.","journal-title":"Curr Alzheimer Res"},{"key":"1139_CR17","doi-asserted-by":"crossref","unstructured":"Rabl M, Clark C, Dayon L, Bowman GL, Popp J. Blood plasma protein profiles of neuropsychiatric symptoms and related cognitive decline in older people. J Neurochemistry. 2022;(0):1\u201313.","DOI":"10.1111\/jnc.15715"},{"issue":"3","key":"1139_CR18","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1111\/j.1365-2796.2004.01380.x","volume":"256","author":"B Winblad","year":"2004","unstructured":"Winblad B, Palmer K, Kivipelto M, Jelic V, Fratiglioni L, Wahlund LO, et al. Mild cognitive impairment--beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. Journal of internal medicine. 2004;256(3):240\u20136.","journal-title":"Journal of internal medicine"},{"issue":"3","key":"1139_CR19","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","volume":"7","author":"GM McKhann","year":"2011","unstructured":"McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, et al. The diagnosis of dementia due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement. 2011;7(3):263\u20139.","journal-title":"Alzheimers Dement"},{"issue":"11","key":"1139_CR20","doi-asserted-by":"publisher","first-page":"2412","DOI":"10.1212\/WNL.43.11.2412-a","volume":"43","author":"JC Morris","year":"1993","unstructured":"Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology. 1993;43(11):2412\u20134.","journal-title":"Neurology"},{"key":"1139_CR21","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.exger.2017.10.013","volume":"100","author":"J Mathys","year":"2017","unstructured":"Mathys J, Gholamrezaee M, Henry H, von Gunten A, Popp J. Decreasing body mass index is associated with cerebrospinal fluid markers of Alzheimer\u2019s pathology in MCI and mild dementia. Exp Gerontol. 2017;100:45\u201353.","journal-title":"Exp Gerontol"},{"issue":"3","key":"1139_CR22","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.jalz.2011.03.008","volume":"7","author":"MS Albert","year":"2011","unstructured":"Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, et al. The diagnosis of mild cognitive impairment due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement. 2011;7(3):270\u20139.","journal-title":"Alzheimers Dement"},{"key":"1139_CR23","first-page":"385","volume":"30","author":"E Michel","year":"2005","unstructured":"Michel E, Robert P, Boulhassass R, Lafont V, Baudu C, Bertogliati C, et al. Validation of the short version of the Neuropsychiatric inventory (NPI-Q). 2005;30:385\u201390.","journal-title":"Validation of the short version of the Neuropsychiatric inventory (NPI-Q)."},{"issue":"2","key":"1139_CR24","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1176\/jnp.12.2.233","volume":"12","author":"DI Kaufer","year":"2000","unstructured":"Kaufer DI, Cummings JL, Ketchel P, Smith V, MacMillan A, Shelley T, et al. Validation of the NPI-Q, a brief clinical form of the Neuropsychiatric Inventory. J Neuropsychiatry Clin Neurosci. 2000;12(2):233\u20139.","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"1139_CR25","doi-asserted-by":"crossref","unstructured":"Saari T, Koivisto A, Hintsa T, Hanninen T, Hallikainen I. Psychometric properties of the neuropsychiatric inventory: a review. J Alzheimers Dis. 2022;86(4):1485-99.","DOI":"10.3233\/JAD-200739"},{"key":"1139_CR26","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.bbi.2017.01.020","volume":"62","author":"J Popp","year":"2017","unstructured":"Popp J, Oikonomidi A, Tautvydaite D, Dayon L, Bacher M, Migliavacca E, et al. Markers of neuroinflammation associated with Alzheimer\u2019s disease pathology in older adults. Brain, behavior, and immunity. 2017;62:203\u201311.","journal-title":"Brain, behavior, and immunity"},{"issue":"Suppl","key":"1139_CR27","first-page":"S221","volume":"150","author":"EE Baulieu","year":"1996","unstructured":"Baulieu EE, Robel P. Dehydroepiandrosterone and dehydroepiandrosterone sulfate as neuroactive neurosteroids. J Endocrinol. 1996;150(Suppl):S221\u201339.","journal-title":"J Endocrinol"},{"issue":"20","key":"1139_CR28","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2013.281053","volume":"310","author":"World Medical Association","year":"2013","unstructured":"World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310(20):2191\u20134.","journal-title":"JAMA"},{"key":"1139_CR29","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.schres.2019.06.023","volume":"213","author":"A Subramaniam","year":"2019","unstructured":"Subramaniam A, LoPilato A, Walker EF. Psychotropic medication effects on cortisol: implications for research and mechanisms of drug action. Schizophrenia research. 2019;213:6\u201314.","journal-title":"Schizophrenia research"},{"issue":"4","key":"1139_CR30","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/j.jalz.2018.03.002","volume":"14","author":"DS Knopman","year":"2018","unstructured":"Knopman DS, Haeberlein SB, Carrillo MC, Hendrix JA, Kerchner G, Margolin R, et al. The National Institute on Aging and the Alzheimer\u2019s Association Research Framework for Alzheimer\u2019s disease: perspectives from the research roundtable. Alzheimers Dement. 2018;14(4):563\u201375.","journal-title":"Alzheimers Dement"},{"issue":"Supplement_1","key":"1139_CR31","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1093\/geroni\/igab046.1691","volume":"5","author":"F Dong","year":"2021","unstructured":"Dong F, Perez GA, Hodgson N, Hwang Y. Relationships between salivary cortisol slope and neuropsychiatric symptoms in persons living with dementia. Innov Aging. 2021;5(Supplement_1):437.","journal-title":"Innov Aging"},{"key":"1139_CR32","doi-asserted-by":"crossref","unstructured":"Chang YS, Wu YH, Wang C-J, Tang S-H, Chen HL. The relationship between thyroid status, cortisol level, cognition and neuropsychiatric symptoms in patients with Alzheimer disease. Neuropsychiatry (London). 2018;(3);786\u201393.","DOI":"10.4172\/Neuropsychiatry.1000404"},{"issue":"3","key":"1139_CR33","doi-asserted-by":"publisher","first-page":"813","DOI":"10.3233\/JAD-190394","volume":"71","author":"A Pedrinolla","year":"2019","unstructured":"Pedrinolla A, Tamburin S, Brasioli A, Sollima A, Fonte C, Muti E, et al. An indoor therapeutic garden for behavioral symptoms in Alzheimer\u2019s disease: a randomized controlled trial. J Alzheimers Dis. 2019;71(3):813\u201323.","journal-title":"J Alzheimers Dis"},{"key":"1139_CR34","doi-asserted-by":"crossref","unstructured":"Chojnowska S, Ptaszynska-Sarosiek I, Kepka A, Knas M, Waszkiewicz N. Salivary biomarkers of stress, anxiety and depression. J Clin Med. 2021;10(3):517.","DOI":"10.3390\/jcm10030517"},{"key":"1139_CR35","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.psyneuen.2015.10.014","volume":"63","author":"M Belvederi Murri","year":"2016","unstructured":"Belvederi Murri M, Prestia D, Mondelli V, Pariante C, Patti S, Olivieri B, et al. The HPA axis in bipolar disorder: systematic review and meta-analysis. Psychoneuroendocrinology. 2016;63:327\u201342.","journal-title":"Psychoneuroendocrinology"},{"key":"1139_CR36","doi-asserted-by":"publisher","first-page":"974","DOI":"10.3389\/fpsyt.2019.00974","volume":"10","author":"LS Nandam","year":"2019","unstructured":"Nandam LS, Brazel M, Zhou M, Jhaveri DJ. Cortisol and major depressive disorder-translating findings from humans to animal models and back. Frontiers in psychiatry. 2019;10:974.","journal-title":"Frontiers in psychiatry"},{"key":"1139_CR37","doi-asserted-by":"crossref","unstructured":"Mikulska J, Juszczyk G, Gawronska-Grzywacz M, Herbet M. HPA axis in the pathomechanism of depression and schizophrenia: new therapeutic strategies based on its participation. Brain Sci. 2021;11(10):1298.","DOI":"10.3390\/brainsci11101298"},{"key":"1139_CR38","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.conb.2019.12.003","volume":"62","author":"LM Frankiensztajn","year":"2020","unstructured":"Frankiensztajn LM, Elliott E, Koren O. The microbiota and the hypothalamus-pituitary-adrenocortical (HPA) axis, implications for anxiety and stress disorders. Current opinion in neurobiology. 2020;62:76\u201382.","journal-title":"Current opinion in neurobiology"},{"key":"1139_CR39","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.yfrne.2015.12.001","volume":"41","author":"J Herbert","year":"2016","unstructured":"Herbert J, Lucassen PJ. Depression as a risk factor for Alzheimer\u2019s disease: genes, steroids, cytokines and neurogenesis - what do we need to know? Frontiers in neuroendocrinology. 2016;41:153\u201371.","journal-title":"Frontiers in neuroendocrinology"},{"issue":"2","key":"1139_CR40","doi-asserted-by":"publisher","first-page":"368504211019856","DOI":"10.1177\/00368504211019856","volume":"104","author":"T Theorell","year":"2021","unstructured":"Theorell T, Engstrom G, Hallinder H, Lennartsson AK, Kowalski J, Emami A. The use of saliva steroids (cortisol and DHEA-s) as biomarkers of changing stress levels in people with dementia and their caregivers: a pilot study. Sci Prog. 2021;104(2):368504211019856.","journal-title":"Sci Prog"},{"issue":"7","key":"1139_CR41","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1212\/01.WNL.0000052994.54660.58","volume":"60","author":"OM Wolkowitz","year":"2003","unstructured":"Wolkowitz OM, Kramer JH, Reus VI, Costa MM, Yaffe K, Walton P, et al. DHEA treatment of Alzheimer\u2019s disease: a randomized, double-blind, placebo-controlled study. Neurology. 2003;60(7):1071\u20136.","journal-title":"Neurology"},{"key":"1139_CR42","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.jad.2014.02.003","volume":"158","author":"H Nabeta","year":"2014","unstructured":"Nabeta H, Mizoguchi Y, Matsushima J, Imamura Y, Watanabe I, Tateishi T, et al. Association of salivary cortisol levels and later depressive state in elderly people living in a rural community: a 3-year follow-up study. Journal of affective disorders. 2014;158:85\u20139.","journal-title":"Journal of affective disorders"},{"issue":"1","key":"1139_CR43","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/s13195-022-01040-5","volume":"14","author":"K Steichele","year":"2022","unstructured":"Steichele K, Keefer A, Dietzel N, Graessel E, Prokosch HU, Kolominsky-Rabas PL. The effects of exercise programs on cognition, activities of daily living, and neuropsychiatric symptoms in community-dwelling people with dementia-a systematic review. Alzheimers Res Ther. 2022;14(1):97.","journal-title":"Alzheimers Res Ther"},{"issue":"5","key":"1139_CR44","doi-asserted-by":"publisher","first-page":"396","DOI":"10.4103\/ijem.IJEM_162_20","volume":"24","author":"N Kumar","year":"2020","unstructured":"Kumar N, Jarial KDS, Bhansali A, Nehra R, Vyas S, Walia R. Neurocognitive functions and brain volume in patients with endogenous Cushing\u2019s syndrome before and after curative surgery. Indian J Endocrinol Metab. 2020;24(5):396\u2013401.","journal-title":"Indian J Endocrinol Metab"},{"issue":"8","key":"1139_CR45","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1176\/appi.ajp.2020.19080848","volume":"177","author":"JB Dwyer","year":"2020","unstructured":"Dwyer JB, Aftab A, Radhakrishnan R, Widge A, Rodriguez CI, Carpenter LL, et al. Hormonal treatments for major depressive disorder: state of the art. The American journal of psychiatry. 2020;177(8):686\u2013705.","journal-title":"The American journal of psychiatry"},{"key":"1139_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.steroids.2019.108507","volume":"153","author":"P Sahu","year":"2020","unstructured":"Sahu P, Gidwani B, Dhongade HJ. Pharmacological activities of dehydroepiandrosterone: a review. Steroids. 2020;153:108507.","journal-title":"Steroids"},{"issue":"1","key":"1139_CR47","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.yfrne.2008.11.002","volume":"30","author":"N Maninger","year":"2009","unstructured":"Maninger N, Wolkowitz OM, Reus VI, Epel ES, Mellon SH. Neurobiological and neuropsychiatric effects of dehydroepiandrosterone (DHEA) and DHEA sulfate (DHEAS). Frontiers in neuroendocrinology. 2009;30(1):65\u201391.","journal-title":"Frontiers in neuroendocrinology"},{"issue":"1","key":"1139_CR48","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/0165-1781(82)90040-3","volume":"6","author":"L Bertilsson","year":"1982","unstructured":"Bertilsson L, Asberg M, Lantto O, Scalia-Tomba GP, Traskman-Bendz L, Tybring G. Gradients of monoamine metabolites and cortisol in cerebrospinal fluid of psychiatric patients and healthy controls. Psychiatry research. 1982;6(1):77\u201383.","journal-title":"Psychiatry research"},{"key":"1139_CR49","doi-asserted-by":"crossref","unstructured":"Mroczek M, Clark C, Dayon L, Bowman GL, Popp J. Cerebrospinal fluid proteome alterations associated with neuropsychiatric symptoms in cognitive decline and Alzheimer\u2019s disease. Cells. 2022;11(6):1030.","DOI":"10.3390\/cells11061030"},{"issue":"6","key":"1139_CR50","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/j.jalz.2013.12.023","volume":"10","author":"FH Duits","year":"2014","unstructured":"Duits FH, Teunissen CE, Bouwman FH, Visser PJ, Mattsson N, Zetterberg H, et al. The cerebrospinal fluid \u201cAlzheimer profile\u201d: easily said, but what does it mean? Alzheimers Dement. 2014;10(6):713\u2013723 e712.","journal-title":"Alzheimers Dement"},{"issue":"1","key":"1139_CR51","volume":"14","author":"FH Bouwman","year":"2022","unstructured":"Bouwman FH, Frisoni GB, Johnson SC, Chen X, Engelborghs S, Ikeuchi T, et al. Clinical application of CSF biomarkers for Alzheimer\u2019s disease: from rationale to ratios. Alzheimers Dement (Amst). 2022;14(1):e12314.","journal-title":"Alzheimers Dement (Amst)"},{"issue":"10043","key":"1139_CR52","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/S0140-6736(15)01124-1","volume":"388","author":"P Scheltens","year":"2016","unstructured":"Scheltens P, Blennow K, Breteler MM, de Strooper B, Frisoni GB, Salloway S, et al. Alzheimer\u2019s disease. Lancet. 2016;388(10043):505\u201317.","journal-title":"Lancet"},{"issue":"4","key":"1139_CR53","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","volume":"14","author":"CR Jack Jr","year":"2018","unstructured":"Jack CR Jr, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, et al. NIA-AA Research Framework: toward a biological definition of Alzheimer\u2019s disease. Alzheimers Dement. 2018;14(4):535\u201362.","journal-title":"Alzheimers Dement"},{"issue":"3","key":"1139_CR54","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/j.neurobiolaging.2007.07.007","volume":"30","author":"J Popp","year":"2009","unstructured":"Popp J, Schaper K, Kolsch H, Cvetanovska G, Rommel F, Klingmuller D, et al. CSF cortisol in Alzheimer\u2019s disease and mild cognitive impairment. Neurobiol Aging. 2009;30(3):498\u2013500.","journal-title":"Neurobiol Aging"},{"issue":"2","key":"1139_CR55","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1016\/j.neurobiolaging.2014.10.031","volume":"36","author":"J Popp","year":"2015","unstructured":"Popp J, Wolfsgruber S, Heuser I, Peters O, Hull M, Schroder J, et al. Cerebrospinal fluid cortisol and clinical disease progression in MCI and dementia of Alzheimer\u2019s type. Neurobiol Aging. 2015;36(2):601\u20137.","journal-title":"Neurobiol Aging"}],"container-title":["Alzheimer's Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-022-01139-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13195-022-01139-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-022-01139-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,19]],"date-time":"2022-12-19T05:07:10Z","timestamp":1671426430000},"score":1,"resource":{"primary":{"URL":"https:\/\/alzres.biomedcentral.com\/articles\/10.1186\/s13195-022-01139-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,19]]},"references-count":55,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["1139"],"URL":"https:\/\/doi.org\/10.1186\/s13195-022-01139-9","relation":{},"ISSN":["1758-9193"],"issn-type":[{"value":"1758-9193","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,19]]},"assertion":[{"value":"27 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 December 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Vaud Cantonal Commission on Ethics in Human Research approved this study (No. 171\/2013), and all participants or their legal representatives provided written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"JP received consultation honoraria from Nestle Institute of Health Sciences, Innovation Campus, EPFL, Lausanne, Switzerland; Ono Pharma; OM Pharma; and Fujirebio Europe, all unrelated to the present work. The other authors declare no potential conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"190"}}